Scarica l'app Stockscreener
0.4546
6.13%
0.0263
Dopo l'orario di chiusura:
.47
0.0155
+3.40%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings - TradingView
Insider Traders Lose US$287k As Jasper Therapeutics Drops - simplywall.st
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Price to earnings forward of Jasper Therapeutics, Inc. – BOATS:JSPRW - TradingView
Jasper Therapeutics Inc (JSPRW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jasper Therapeutics StockAnalyst consensus and weekly review - Ad-hoc-news.de
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPRW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPRW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPRW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPRW) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPRW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
JSPR | Jasper Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44FRAMA Signal - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Jasper Therapeutics (JSPR) Hovers Near Support After Marginal DeclineAD Line Divergence - dars.gov.et
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
JSPRJasper Therapeutics Inc Stock Price and Quote - Finviz
Jasper Therapeutics (JSPR) Edges Higher: Small-Cap Biotech Tests Resistance at $0.95ETF Flow - The Legal Advocate
Jasper Therapeutics (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - The Legal Advocate
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):